arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Bluejay Diagnostics, Inc.

BJDX

$0.96 ▲ +0.02 (+2.33%) at close

7 Visible periods

21 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Bluejay Diagnostics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -91.9% ↗

FCF / Share $-13.87

Trailing P/E —

Price / Book 0.1x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-6.85M

↑ +11.3% —

FCF / Share Free cash flow per share

$-13.87

↓ -3027.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	96.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	87.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-789352.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-12.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	11.3% Fair ↑ Fair Improving Year-over-year change in net income	22.5% Good ↑ Good Improving Year-over-year change in net income	-7.1% Weak ↑ Weak Improving Year-over-year change in net income	-166.5% Weak Weak Year-over-year change in net income	-201.2% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	—	—	—	13.9% Fair Fair Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
FCF / Net Income (x)	0.91x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.26x Good Good Free cash flow relative to reported net income Optimal: > 1x	0.44x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-91.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-98.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-281.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-63.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	22.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-97.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-107.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-211.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-68.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-15.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-78.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-114.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-864%)	-134.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-998%)	—	-80.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-637%)	-17.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-214%)	27.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+84%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	—	—	—	-25598.29x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-507.89x Weak Weak Operating income divided by interest expense Optimal: > 5x	-20.18x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-5.16M	$-4.30M	$-2.21M	$-10.11M	$-19.05M	$-912.36K	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	—	—	—	$0.01	—	—	—
Basic EPS, GAAP (USD)	$-15.25	$-456.75	$-3.63K	$-0.46	$-0.41	—	—
Free Cash Flow per Share (USD)	$-13.87	—	—	$-0.44	$-0.52	—	—
Book Value per Share (USD)	$9.88	$41.37	—	$0.57	$1.01	$-1.34	—
Tangible Book Value per Share (USD)	$9.88	$41.37	—	$0.57	$1.01	$-1.34	—
Basic Weighted Avg Shares (shares)	449,043	45,848	2,741	20.16M	8.52M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$4.34M	$4.09M	$1.45M	$10.15M	$20.02M	—	—
Total Equity (USD)	$5.98M	$5.73M	$2.89M	$11.54M	$20.38M	$-4.21M	$-2.93M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	$249.04K	—	—	—
Depreciation Expense (USD)	$74.18K	$75.62K	$648.71K	—	—	—	—
Net Income, GAAP (USD)	$-6.85M	$-7.72M	$-9.95M	$-9.30M	$-3.49M	$-1.16M	—
Operating Cash Flow (USD)	$-6.05M	$-7.82M	$-8.31M	$-7.74M	$-4.37M	$-508.71K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 7 years · 27 quarters

Bluejay Diagnostics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BJDX with peers